EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elicitation of immune responses against Nipah virus by an engineered synthetic DNA vaccine

Hyeree Choi, Sagar B. Kudchodkar, Ziyang Xu, Michelle Ho, Peng Xiao, Stephanie Ramos, Laurent Humeau, David B. Weiner, Kar Muthumani

Frontiers in Virology · 10.11.2022 · 2

DOI: 10.3389/fviro.2022.968338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Virology, online erschienen am 10.11.2022. Verfasst von Hyeree Choi und 8 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nipah virus (NiV) is a re-emerging pathogen that causes severe disease in animals and humans. Current treatment measures for NiV infection are insufficient, and there is no approved vaccine against NiV for either humans or animals. Nipah virus is listed as a high-priority pathogen for vaccine and therapeutic research by the World Health Organization (WHO). In the present study, we employed synthetic enhanced DNA technologies developed to design and produce novel consensus NiV Fusion (NiV-F) and Glycoprotein (NiV-G) antigen sequences for inclusion in synthetic DNA vaccines for NiV. The expression of each vaccine antigen was confirmed in vitro using immune-binding assays. Electroporation-enhanced intramuscular injection of each NiV-F and NiV-G into mice induced potent cellular immune responses to multiple epitopes of NiV-G and NiV-F that included antigen-specific CD8 + T cells. Both vaccines elicited high antibody titers in mice, with a single immunization sufficient to seroconvert 100% of immunized animals. Additionally, the NiV-F vaccine also induced antibodies to neutralize NiV-F-pseudotyped virus particles. These data support further study of these novel synthetic enhanced NiV nucleic acid-based antigens as potential components of an effective vaccine against the Nipah virus.

Zitieren

APA

Choi, H., Kudchodkar, S. B., Xu, Z., Ho, M., Xiao, P., Ramos, S., Humeau, L., Weiner, D. B., & Muthumani, K. (2022). Elicitation of immune responses against Nipah virus by an engineered synthetic DNA vaccine. Frontiers in Virology, 2. https://doi.org/10.3389/fviro.2022.968338

Vancouver

Choi H, Kudchodkar SB, Xu Z, Ho M, Xiao P, Ramos S, et al. Elicitation of immune responses against Nipah virus by an engineered synthetic DNA vaccine. Frontiers in Virology. 2022;2. doi:10.3389/fviro.2022.968338

BibTeX
@article{Choi2022,
  author = {Choi, Hyeree and Kudchodkar, Sagar B. and Xu, Ziyang and Ho, Michelle and Xiao, Peng and Ramos, Stephanie and Humeau, Laurent and Weiner, David B. and Muthumani, Kar},
  title = {Elicitation of immune responses against Nipah virus by an engineered synthetic DNA vaccine},
  journal = {Frontiers in Virology},
  year = {2022},
  volume = {2},
  doi = {10.3389/fviro.2022.968338}
}
Kostenlos starten →